18 Jul Nanoscope Therapeutics
Samarendra Mohanty, President
Oct. 6 | 11:15am | FLW Ballroom G
Dallas, TX
(Private)
Nanoscope Therapeutics has achieved a historic technological breakthrough in the field of gene therapy by developing Multi-Characteristic Opsin (MCO), an innovative optogenetic gene therapy platform to treat Retinal Disease-related blindness. Retinal Dystrophies (RDs) are the leading cause of blindness in working-age people, and there is presently no effective treatment for these diseases. Nanoscope developed MCO therapy as the first-ever treatment to restore return-to-life vision in patients that are profoundly blind due to RDs. MCO has been utilized in human patients across three clinical trials. Hundreds of gene mutations cause RDs, meaning a classical gene therapy approach would require developing hundreds of therapies to address RDs. Because RD progression is permanent, classical gene therapies can only benefit patients early in disease, leaving little hope for patients that have already lost their vision. MCO therapy has the potential to treat all RD patients, regardless of their mutation, or state of disease.